<DOC>
	<DOCNO>NCT00194935</DOCNO>
	<brief_summary>The purpose study find safety feasibility weekly topotecan consolidation therapy patient ovarian cancer .</brief_summary>
	<brief_title>Weekly Topotecan Therapy Patients With Ovarian Cancer</brief_title>
	<detailed_description>Patients Stage IIIC IV optimally-debulked ovarian cancer treat 6 cycle ( every 3 week ) carboplatin ( AUC 5 ) paclitaxel ( 175 mg/m2 ) . Patients demonstrate complete clinical response regimen treat topotecan consolidation ( 4 mg/m2 weekly x 8 week one cycle follow break 9th week ) maximum 3 cycle . Primary endpoint toxicity determination appropriate dose , schedule , duration topotecan consolidation trial .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Patients must histopathologic diagnosis epithelial ovarian cancer . Patients must complete frontline chemotherapy clinically NED ( CA 125 &lt; 35 , negative CT scan , negative physical exam ) . Patients may second look laparoscopy , however , must gross disease present ( microscopic disease pathologically negative ) . Patients must myelosuppressive therapy within four week initiate topotecan therapy . Topotecan treatment must begin within 10 week follow last cycle initial chemotherapy . Patients may one prior chemotherapy regimen . Patients concomitant malignancy squamous cell basal cell skin cancer . Patients pregnant breastfeeding .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Cancer Ovary</keyword>
</DOC>